Mn‐loaded apoferritin: a highly sensitive MRI imaging probe for the detection and characterization of hepatocarcinoma lesions in a transgenic mouse model
Open Access
- 26 April 2012
- journal article
- research article
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 7 (3) , 281-288
Abstract
Mn‐Apo is a highly sensitive MRI contrast agent consisting of ca. 1000 manganese atoms entrapped in the inner cavity of apoferritin. Part of the metallic payload is in the form of Mn2+ ions that endow the nano‐sized system with a very high relaxivity that can be exploited to detect hepatocellular carcinoma in mice. Cellular studies showed that Mn‐Apo is readily taken up by normal hepatocytes via the ferritin transporting route. Conversely, hepatoma cells (HTC) displayed a markedly reduced ability to entrap Mn‐Apo from the culture medium. The i.v. administration of Mn‐Apo into C57BL/6 J mice resulted in a marked liver tissue hyperintensity in T1‐weighted MR image 20 min after injection. When injected into HBV‐tg transgenic mice that spontaneously develop hepatocellular carcinoma (HCC), Mn‐Apo allowed a clear delineation of healthy liver tissue and tumor lesions as hyperintense and hypointense T1‐weighted MR images, respectively. Immunohistochemistry analysis correlated Mn‐Apo cellular uptake to SCARA5 receptor expression. When the MRI contrast induced by Mn‐Apo was compared with that induced by Gd–BOPTA (a commercial contrast agent known to enter mouse hepatocytes through organic anion transporters) it was found that only some of the lesions were detected by both agents while others could only be visualized by one of the two. These results suggest that Mn‐Apo may be useful to detect otherwise invisible lesions and that the extent of its uptake directly reports the expression/regulation of SCARA5 receptors. Mn‐Apo contrast‐enhanced MR images may therefore contribute to improving HCC lesion detection and characterization. Copyright © 2012 John Wiley & Sons, Ltd.Keywords
This publication has 31 references indexed in Scilit:
- The Etiology of Hepatocellular Carcinoma and Consequences for TreatmentThe Oncologist, 2010
- Treatment of Intermediate/Advanced Hepatocellular Carcinoma in the Clinic: How Can Outcomes Be Improved?The Oncologist, 2010
- Hepatic Uptake of the Magnetic Resonance Imaging Contrast Agent Gd-EOB-DTPA: Role of Human Organic Anion TransportersDrug Metabolism and Disposition, 2010
- Magnetic resonance imaging of hepatocellular carcinoma: a pictorial review of novel insights into pathophysiological features revealed by magnetic resonance imagingJournal of Hepato-Biliary-Pancreatic Sciences, 2009
- Hepatobiliary-specific MR Contrast Agents: Role in Imaging the Liver and Biliary TreeRadioGraphics, 2009
- Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinomaJournal of Gastroenterology, 2009
- Hepatocellular carcinoma: Conventional MRI findings including gadolinium-enhanced dynamic imagingEuropean Journal of Radiology, 2006
- MRI in detection of hepatocellular carcinoma (HCC)Cancer Imaging, 2005
- Molecular Mechanisms for the Hepatic Uptake of Magnetic Resonance Imaging Contrast AgentsBiochemical and Biophysical Research Communications, 1999
- Dynamic MR imaging of the liver with Gd-DTPA: initial clinical resultsAmerican Journal of Roentgenology, 1989